Skip to main content
. Author manuscript; available in PMC: 2022 May 26.
Published in final edited form as: Mol Cancer Res. 2021 Jan 29;19(5):913–920. doi: 10.1158/1541-7786.MCR-20-0738

Figure 7: Gilteritinib down-regulates CD30 surface expression in ALCL cells.

Figure 7:

SU-DHL-1 cells were treated for 24 hours with indicated concentrations of gilteritinib and stained with anti-CD30-FITC along with respective isotype control antibodies. The CD30 positive cells were measured by flow cytometry. Columns represent the mean of three independent experiments; bars represent the SEM.